Abstract
Evasion of apoptosis may contribute to poor treatment response in pediatric acute lymphoblastic leukemia (ALL), calling for novel treatment strategies. Here, we report that inhibitors of apoptosis (IAPs) at subtoxic concentrations cooperate with various anticancer drugs (that is, AraC, Gemcitabine, Cyclophosphamide, Doxorubicin, Etoposide, Vincristine and Taxol) to induce apoptosis in ALL cells in a synergistic manner as calculated by combination index and to reduce long-term clonogenic survival. Importantly, we identify RIP1 as a critical regulator of this synergism of IAP inhibitors and AraC that mediates the formation of a RIP1/FADD/caspase-8 complex via an autocrine/paracrine loop of tumor necrosis factor-α (TNFα). Knockdown of RIP1 abolishes formation of this complex and subsequent activation of caspase-8 and -3, mitochondrial perturbations and apoptosis. Similarly, inhibition of RIP1 kinase activity by Necrostatin-1 or blockage of TNFα by Enbrel inhibits IAP inhibitor- and AraC-triggered interaction of RIP1, FADD and caspase-8 and apoptosis. In contrast to malignant cells, IAP inhibitors and AraC at equimolar concentrations are non-toxic to normal peripheral blood lymphocytes or mesenchymal stromal cells. Thus, our findings provide first evidence that IAP inhibitors present a promising strategy to prime childhood ALL cells for chemotherapy-induced apoptosis in a RIP1-dependent manner. These data have important implications for developing apoptosis-targeted therapies in childhood leukemia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Pui CH, Relling MV, Downing JR . Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535–1548.
Stanulla M, Cario G, Meissner B, Schrauder A, Moricke A, Riehm H et al. Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study Group. Blood Cells Mol Dis 2007; 39: 160–163.
Fulda S . Tumor resistance to apoptosis. Int J Cancer 2009; 124: 511–515.
Fulda S . Therapeutic opportunities for counteracting apoptosis resistance in childhood leukaemia. Br J Haematol 2009; 145: 441–454.
Fulda S, Debatin KM . Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4798–4811.
Ashkenazi A . Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 2008; 19: 325–331.
Kroemer G, Galluzzi L, Brenner C . Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99–163.
LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG . IAP-targeted therapies for cancer. Oncogene 2008; 27: 6252–6275.
Eckelman BP, Salvesen GS, Scott FL . Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 2006; 7: 988–994.
Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689–700.
Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P . RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ 2007; 14: 400–410.
Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007; 131: 669–681.
Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131: 682–693.
Wang L, Du F, Wang X . TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008; 133: 693–703.
Hundsdoerfer P, Dietrich I, Schmelz K, Eckert C, Henze G . XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL. Pediatr Blood Cancer 2010; 55: 260–266.
Wuchter C, Richter S, Oltersdorf D, Karawajew L, Ludwig WD, Tamm I . Differences in the expression pattern of apoptosis-related molecules between childhood and adult de novo acute myeloid leukemia. Haematologica 2004; 89: 363–364.
Fakler M, Loeder S, Vogler M, Schneider K, Jeremias I, Debatin KM et al. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 2009; 113: 1710–1722.
Oost TK, Sun C, Armstrong RC, Al-Assaad AS, Betz SF, Deckwerth TL et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 2004; 47: 4417–4426.
Chao B, Deckwerth TL, Furth PS, Linton SD, Spada AP, Ullman BR et al., inventors; Tetrapeptide Analogs, United States patent PCT/US2005/024700. 2006 16.02.
Fulda S, Strauss G, Meyer E, Debatin KM . Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. Blood 2000; 95: 301–308.
Vogler M, Durr K, Jovanovic M, Debatin KM, Fulda S . Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 2007; 26: 248–257.
Mohr A, Zwacka RM, Debatin KM, Stahnke K . A novel method for the combined flow cytometric analysis of cell cycle and cytochrome c release. Cell Death Differ 2004; 11: 1153–1154.
Chou TC . The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC (ed). Synergism and antagonism in chemotherapy. Academic Press: San Diego, USA, 1991, pp 61–102.
Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007; 12: 445–456.
Ting AT, Pimentel-Muinos FX, Seed B . RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis. Embo J 1996; 15: 6189–6196.
Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1: 112–119.
Degterev A, Hitomi J, Germscheid M, Ch’en IL, Korkina O, Teng X et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008; 4: 313–321.
Loeder S, Drensek A, Jeremias I, Debatin KM, Fulda S . Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis. Int J Cancer 2010; 126: 2216–2228.
Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 2009; 69: 2425–2434.
Vellanki SH, Grabrucker A, Liebau S, Proepper C, Eramo A, Braun V et al. Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia 2009; 11: 743–752.
Loeder S, Zenz T, Schnaiter A, Mertens D, Winkler D, Dohner H et al. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res 2009; 69: 8977–8986.
Fulda S . Inhibitor of apoptosis proteins in hematological malignancies. Leukemia 2009; 23: 467–476.
Acknowledgements
We thank C Hulford and M Luzzio (Pfizer Inc., Groton, CN) for providing IAP inhibitors and S Zhou (Ulm, Germany) for help with the analysis of TNFα levels. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft (to SF), José Carreras Leukämie-Stiftung (to SF), European Community (to SF and PV), IAP6/18 (to SF and PV). PV holds a Methusalem grant (BOF09/01M00709) from the Flemish Government. MB has a tenure track position within Multidisciplinary Research Program from the Ghent University (GROUP-ID).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Löder, S., Fakler, M., Schoeneberger, H. et al. RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. Leukemia 26, 1020–1029 (2012). https://doi.org/10.1038/leu.2011.353
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.353
Keywords
This article is cited by
-
Bcl-3 promotes TNF-induced hepatocyte apoptosis by regulating the deubiquitination of RIP1
Cell Death & Differentiation (2022)
-
Smac mimetic suppresses tunicamycin-induced apoptosis via resolution of ER stress
Cell Death & Disease (2019)
-
MLKL mediates apoptosis via a mutual regulation with PERK/eIF2α pathway in response to reactive oxygen species generation
Apoptosis (2018)
-
Inhibitors of apoptosis: clinical implications in cancer
Apoptosis (2017)
-
Intrinsic and chemo-sensitizing activity of SMAC-mimetics on high-risk childhood acute lymphoblastic leukemia
Cell Death & Disease (2016)